8-K: CV Sciences Reports Stable Revenue, Nears Profitability in Q3 2024

CV Sciences reported third quarter 2024 financial results, showing stable revenue and progress towards profitability.

Summary

• CV Sciences reported a revenue of $3.9 million for the third quarter of 2024, a slight decrease from $4.1 million in the same quarter of 2023 and $4.0 million in the second quarter of 2024.
• The company's gross margin was 46.0% for the third quarter of 2024, compared to 45.1% in the third quarter of 2023 and 47.0% in the second quarter of 2024.
• CV Sciences had a cash balance of $1.0 million at the end of the quarter, down from $1.3 million at the end of 2023.
• The company launched a new line of cannabinoid-free supplements called +PlusHLTH, which includes products for cognitive enhancement, stress relief, and metabolism support.
• CV Sciences maintained its position as the top-selling hemp extract brand in the natural product retail sales channel.
• The company entered into a financing agreement with Streeterville for net proceeds of $0.9 million.
• The adjusted EBITDA loss for the third quarter of 2024 was $75,000, indicating the company is close to achieving operating cash flow break-even.
• The company experienced a 5% decrease in sales compared to the third quarter of 2023, primarily due to a 9% decline in B2B sales.
• The total number of units sold decreased by 7.9%, with a slight decrease of 0.5% in average sales prices per unit.
• The operating loss for the third quarter of 2024 was $0.3 million, an improvement from the $0.4 million loss in the same quarter of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenue is slightly down, the company is showing progress in gross margins and moving towards profitability. The launch of new products and the financing agreement are positive signs, but the regulatory challenges and cash position are concerns.

Positives

• Gross margins have improved throughout 2024 compared to previous years.
• The company is close to achieving operating cash flow break-even.
• CV Sciences is committed to innovation and cost-efficient execution.
• The company is exploring M&A opportunities to improve revenue and profitability.
• The company has launched new products including pet chews and a new supplement line.
• The company has a strong position as the top-selling hemp extract brand in the natural products market.

Negatives

• Revenue decreased by 5% compared to the third quarter of 2023.
• B2B sales declined by 9% due to regulatory challenges.
• The total number of units sold decreased by 7.9%.
• The company's cash balance decreased from $1.3 million at the end of 2023 to $1.0 million at the end of Q3 2024.
• The company experienced a net loss of $456,000 for the quarter.

Risks

• The company faces challenges due to the patchwork of state regulations for CBD.
• Forward-looking statements are subject to risks, uncertainties, and assumptions that are difficult to predict.
• Actual outcomes and results may differ materially from forward-looking statements.
• The company's ability to grow revenue in 2025 is dependent on acquisitions and new product innovations.
• The company's financial performance is subject to market conditions and competition.

Future Outlook

The company anticipates further gross margin improvements in 2025 and expects to organically grow its business and pursue additional M&A opportunities to improve top-line revenue, profitability, and shareholder value.

Management Comments

• We are pleased with our third 2024 results.
• Revenues for our core business remained stable around the $4 million range during the third quarter 2024 despite a challenging environment.
• With our recent acquisitions and new product innovations, we believe that we are nicely positioned to grow our revenue in 2025.
• Our gross margins have improved throughout 2024 compared to previous years and we anticipate making further gross margin improvements in 2025.
• Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow.
• We look forward to organically grow our business and pursue additional M&A opportunities in the near future to improve our top-line revenue, profitability and shareholder value.

Industry Context

The company operates in the competitive consumer wellness market, specializing in hemp extracts and plant-based foods. The results reflect the challenges of navigating varying state regulations for CBD products, while also highlighting the company's efforts to innovate and expand its product offerings.

Comparison to Industry Standards

• CV Sciences competes with other companies in the hemp-derived CBD and nutraceutical space, such as Charlotte's Web and Canopy Growth, though direct comparisons are difficult due to varying business models and reporting standards.
• The company's gross margin of 46% is within the typical range for consumer packaged goods companies, but may be lower than some higher-margin nutraceutical businesses.
• The adjusted EBITDA loss of $75,000 indicates progress towards profitability, but the company still needs to improve its operating performance to achieve consistent positive cash flow.
• The company's focus on science-backed products and clinical research is a differentiator in the market, but it also requires significant investment.

Stakeholder Impact

• Shareholders may be concerned about the slight decrease in revenue but encouraged by the progress towards profitability.
• Employees may be impacted by the company's cost-cutting measures and focus on efficiency.
• Customers will benefit from the new product launches and the company's commitment to science-backed products.
• Suppliers may be affected by the company's efforts to optimize its supply chain.
• Creditors may be reassured by the company's progress towards profitability.

Next Steps

• The company will host a conference call and webcast to discuss the results.
• The company plans to organically grow its business.
• The company will pursue additional M&A opportunities.
• The company anticipates further gross margin improvements in 2025.

Key Dates

Keywords

hemp extracts, CBD, cannabinoid-free supplements, financial results, gross margin, EBITDA, B2B sales, natural products, nutraceuticals, plant-based foods